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Noonan syndrome is an autosomal dominant disorder characterized by 
short stature, typical craniofacial features, and congenital heart defects. The 
underlying genetic defects were not clear until 2001. This report is the first 
to describe a molecular analysis and associated clinical features of a Turkish 
mother and son, who were clinically diagnosed as Noonan syndrome when 
the boy was referred to our department due to short stature. The analysis 
revealed an A→G transition at position 923 in exon 8 of the PTPN11 gene, 
indicating an Asn308Ser substitution.
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Noonan syndrome (NS, OMIM 163950) is 
an autosomal genetic disorder resulting in 
characteristic features, namely typical facial 
dysmorphology [hypertelorism, epicanthic 
folds, downward-slanting palpebral fissures, 
low-set posteriorly rotated ears with a thick 
helix, a short neck with excess nuchal skin, 
triangular face often appearing coarse or 
myopathic, prominent eyes, and (unilateral 
or bilateral) ptosis], congenital heart defects 
(pulmonary valve stenosis, hypertrophic 
obstructive cardiomyopathy), short stature, 
chest deformities, undescended testicles, and 
mild motor and mental retardation1. This 
condition is reported to be relatively common, 
with an estimated incidence of 1:1,000–1:2,500 
live births; however, the diagnosis is not 
straightforward owing to marked variability 
in expression and facial features becoming 
less noticeable with age1,2. Accordingly, there 
are only a number of reports regarding NS 
from Turkey in the national and international 
medical literature3-5.
It was not until 2001 that one of the underlying 
genetic 325 in NS was recognized. Tartaglia et 
al.6 identified mutations in the PTPN11 gene, 
which encodes the non–receptor type protein 
tyrosine phosphatase (SHP-2) involved in 
cellular response to growth factors, hormones, 
cytokines, and cell adhesion molecules. 
However, PTPN11 mutations account for nearly 
60% of the familial and 40% of the sporadic 
NS cases1. Recently, mutations of molecules 
in the RAS/MAPK cascade, which is required 
in cell proliferation, differentiation, survival 
and cell death, were detected in patients with 
NS without PTPN11 mutations7. Molecular 
diagnosis of NS is not only of importance 
for the confirmation of the clinical diagnosis 
or genetic counseling, but also helps us to 
predict the response to growth hormone (GH) 
treatment8, 9.
This report is the first to describe the molecular 
analysis and associated clinical features of a 
Turkish mother and son, who were clinically 
diagnosed as NS when the boy was referred 
to our department due to short stature.
Case Report
This 12½-year-old boy was referred to our 
department due to short stature. He had been 
short compared to his peers since infancy, 
while birth length was 51 cm (SD 0.38). 
His nutrition had long been poor owing to 
diminished appetite. Balloon valvuloplasty had 
been performed for dysplastic pulmonary valve 
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stenosis when he was 7 months old. Since then, 
no periodic follow-up had been made. His past 
medical history revealed that he was born to 
a 35-year-old mother who had been operated 
for pulmonary valve stenosis at the age of 15 
years. A delay in mental development was 
suggested since his school performance was 
low to moderate. The parents were not related. 
His mother’s height was 160 cm (SDS -0.5) 
and his father’s was 170 cm (SDS -0.92). 
Physical examination revealed the following: 
weight 22.7 kg (below 3rd percentile, SD -
4.2), height 132 cm (below 3rd percentile, 
SD -2.75; According to height centiles for boys in 
Noonan syndrome: 50th percentile), weight for 
height 82%, hypertelorism, downward-slanting 
palpebral fissures, low-set ears, triangular face, 
prominent eyes, ptosis, thick lips, high-arched 
palate, prominent ears, and broad chest. The 
left testis was palpable with a volume of 3 ml, 
but the right testis was not palpable. There 
was no axillary or pubic hair. The remainder 
of the systemic examination was normal. His 
mother had hypertelorism, downward-slanting 
palpebral fissures, triangular face, prominent 
eyes and nasolabial folds, ptosis, and thick 
lips (Fig. 1-Informed consent was obtained for 
use of the photograph). Neither the maternal 
or paternal grandparents nor the father had 
dysmorphologic findings or cardiac disease; 
however, his only sibling (21 years old, M) 
reportedly had the similar but milder phenotype 
without any complaints. Nevertheless, this case 
did not accept to be examined or provide a 
blood sample for molecular study.
Both the patient and his mother were diagnosed 
with NS using the scoring system described 
by van der Burgt (Table I)1. Complete blood 
count and kidney, liver and thyroid function 
tests of our patient were within normal ranges, 
as were the abdominal ultrasonography and 
audiological evaluation. Serum insulin-like 
growth factor (IGF)-I level was 54.5 ng/ml 
(SD -3.33) and IGF binding protein (IGFBP)-
3 level was 3480 ng/ml (SD -0.7). Serum 
follicle- stimulating hormone (FSH) level was 
6.47 mIU/ml, luteinizing hormone (LH) 0.798 
mIU/ml, and total testosterone 25.2 ng/dl. 
Bone age was consistent with 10 years of 
age. Ultrasonography and magnetic resonance 
imaging showed that the right testis (2.6 ml) 
was located intra-abdominally and adjacent 
to the external iliac vascular structures. 
Ophthalmologic examination disclosed myopia 
and astigmatism. Peak levels of GH following 
stimulation with insulin and L-dopa without 
priming were 8.34 ng/ml and 6.5 ng/ml 
(normal, >10 ng/ml), respectively. A bone 
mineral density test revealed a normal Z-
score (0.85). Radiologic examination of the 
skeletal system revealed normal findings. His 
Wechsler Intelligence Scale for Children (WISC-
R) test scores were as follows: verbal IQ 77, 
performance IQ 88 and total IQ 80.
In the DNA diagnostics laboratory of the 
Radboud University Nijmegen Medical 
Centre (The Netherlands), mutation analysis 
of the PTPN11 gene was performed. DNA 
was extracted from blood lymphocytes using 
standard procedures. Nine of the 15 coding 
exons (exons 1, 2, 3, 4, 5, 7, 8, 12, 13, and 14) 
of the PTPN11 gene (NCBI accession number 
NM_002834.3) and their flanking sequences 
were amplified by polymerase chain reaction 
(PCR). Subsequently, sequence analysis was 
performed using a 3730 automated sequencer 
(Applied Biosystems, Foster City, CA). Primer 
sequences and conditions for PCR amplification 
are available upon request. In the DNA of the 
index patient, a pathogenic mutation in exon 8 
of the PTPN11 gene was identified: c.923A>G 
(p.Asn308Ser). The same mutation was found 
to be present in the DNA of his mother.
His target height was 171.5 cm (SD -0.75) 
and predicted adult height was 162.5 cm (SD 
-2.0). GH therapy was started at a dose of 0.25 
mg/kg/week (35 µg/kg/d), which provided a 
Fig. 1. Photograph of the patient and his mother 
demonstrating the changes in facial features with 
age, characteristic of Noonan syndrome: more 
prominent nasolabial folds, thick hooded eyelids, 
and less prominent eyes in the mother. 
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height velocity of 7.2 cm/year. Staged Stephen-
Fowler laparoscopic orchiopexy was performed 
for the right testicle. Educational support was 
planned.
Discussion
The identified mutation in our patient has 
also been detected in numerous studies on 
NS around the world10-12. Lopez-Canti et al.10 
found that the most common PTPN11 mutation 
was the same as ours; however, neither the 
exact frequency and associated clinical features 
nor whether this mutation was detected from 
the related patients was delineated. However, 
there was a single case with Asn308Ser mutation 
in the study of Ferrero et al.11 and the only 
data available regarding this case were short 
stature and minor facial features. Our case 
(typical face dysmorphology plus 4 major and 
1 minor criteria) and his mother (typical face 
dysmorphology plus 2 major criteria) fulfilled 
the clinical diagnostic criteria for NS.
Interestingly, the mutation found in our patient 
was also demonstrated in a family including 
siblings with giant cell lesions in various 
bones in addition to NS phenotype and their 
mother with only NS phenotype without bone 
lesions, consistent with Noonan-like syndrome 
and multiple giant cell lesions (NL/MGCLS, 
OMIM 163955)13,14. However, as in our cases, 
the same Asn308Ser mutation was observed 
in another family with NS that had no known 
bony involvement6. Furthermore, two other 
known NS mutations were detected in two of 
three patients with NL/MGCLS15. As a result, 
it was suggested that NL/MGCLS should 
be considered as part of the NS phenotypic 
spectrum13.
Mean height of patients with NS is around the 
lowest range of the normal growth curve during 
childhood. With delay in puberty, short stature 
becomes more pronounced16. In 2003, Noonan 
et al.17 reported that height of approximately 
two-thirds of the adult males was below the 
10th centile, while in half of them, height was 
below the 3rd centile. Although the mother 
had a normal height (SD score 0.5), our 
patient was significantly short compared to his 
peers (SD score -2.75). GH stimulation tests 
without priming revealed subnormal results. 
Although there are conflicting results regarding 
the GH–IGF-1 axis in patients with NS, such 
as neurosecretory dysfunction, low peak GH 
responses to provocation, normal GH secretion, 
and mild GH resistance, in cases with PTPN11 
mutations, including ours, many children with 
NS have been treated with GH, resulting in 
significant increase in growth velocity especially 
in the first years, as observed in our case16,18. 
Recently, in a long-term observational study 
including a large number of patients, significant 
improvement was reported in near-final height 
SDS of patients with NS (+1.4), similar to that 
seen in Turner syndrome (+1.2), especially 
when the prepubertal treatment duration is 
long19. 
In conclusion, we emphasize herein that 
patients with this relatively common syndrome, 
which has a favorable prognosis with treatment 
of cardiac problems and short stature, can now 
be genetically analyzed and counseled.
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